Posts published in “Insights”

This paper was originally published by Emanuel Almeida Moreira de Oliveira and Karen Luise Lang in Journal of Applied Pharmaceutical Science Vol. 8(08), pp 157-165, August, 2018 under the terms of the…

There is no simple way to explain drug prices, particularly in the US market, where drug prices vary considerably more than they do in other countries. Most Americans are familiar…

This article was originally published by Gerard T. Vondeling, Qi Cao, Maarten J. Postma, and Mark H. Rozenbaum in Applied Health Economics and Health Policy (2018) pp.1-8 under a Creative Commons Attribution-NonCommercial…

This paper was originally published by Witold Jamróz, Joanna Szafraniec, Mateusz Kurek, and Renata Jachowicz in Pharmaceutical Research September 2018, 35:176 under a Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/). Abstract Growing demand…

There are more than 7,000 diseases that are considered “rare,” that is, affecting fewer than 200,000 Americans. Yet around one in ten Americans lives with at least one of these…

A few years ago, there was much talk of the “patent cliff” facing blockbuster drugs like Lipitor and other huge name-brand drugs. The “patent cliff” may have spelled the end…

This article was originally published by Li Du in BMC Medical Ethics 2018 19:29 under a creative commons license. Abstract Background The patenting of human genes has been the subject…

Drug development is one of the world’s most high-risk / high-reward industries, with the vast majority of drugs created never making it to market. Of those that do make it…

Portfolio, Program, and Project Management in the Pharmaceutical and Biotechnology Industries This book describes the way that pharmaceutical projects and programs are currently managed, and offers views from many highly…